Ascendis Pharma (ASND) officer details warrants, RSUs and shares

Rhea-AI Filing Summary

Ascendis Pharma A/S officer SPROGOE KENNETT filed an initial Form 3 showing existing equity holdings, rather than new transactions. The filing lists fully vested and currently exercisable warrants over 5,313, 45,000, 27,000, 22,755 and 14,504 Ordinary Shares at exercise prices of $37.18, $62.17, $108.00, $176.28 and $139.65 per share, respectively. It also reports three blocks of restricted stock units covering 4,246, 3,197 and 9,552 Ordinary Shares, which vest beginning on March 1, 2027 in one‑, two‑ and three‑year installment schedules and have no expiration date. In addition, the officer holds 19,460 Ordinary Shares directly and 110 Ordinary Shares indirectly through children. The footnotes clarify that each restricted stock unit corresponds to a right to receive one American Depositary Share, and each ADS represents one Ordinary Share.

Insider Trade Summary

10 transactions reported

Mixed 10 txns

Insider SPROGOE KENNETT

Role See Remarks

Type	Security	Shares	Price	Value
holding	Warrants	--	--	--
holding	Warrants	--	--	--
holding	Warrants	--	--	--
holding	Warrants	--	--	--
holding	Warrants	--	--	--
holding	Restricted Stock Units	--	--	--
holding	Restricted Stock Units	--	--	--
holding	Restricted Stock Units	--	--	--
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Warrants — 5,313 shares (Direct); Restricted Stock Units — 4,246 shares (Direct); Ordinary Shares — 19,460 shares (Direct); Ordinary Shares — 110 shares (Indirect, By children)

Footnotes (1)

1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share. The warrants are fully vested and currently exercisable. The restricted stock units vest on March 1, 2027 and have no expiration date. Each restricted stock unit represents a contingent right to receive one ADS. The restricted stock units vest in two equal annual installments beginning on March 1, 2027. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SPROGOE KENNETT

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP DK-2900

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	19,460	D
Ordinary Shares(1)	110	I	By children

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	(2)	12/12/2027	Ordinary Shares	5,313	$37.18	D
Warrants	(2)	12/11/2028	Ordinary Shares	45,000	$62.17	D
Warrants	(2)	12/10/2029	Ordinary Shares	27,000	$108	D
Warrants	(2)	12/10/2030	Ordinary Shares	22,755	$176.28	D
Warrants	(2)	12/09/2031	Ordinary Shares	14,504	$139.65	D
Restricted Stock Units	(3)	(3)	Ordinary Shares	4,246	(4)	D
Restricted Stock Units	(5)	(5)	Ordinary Shares	3,197	(4)	D
Restricted Stock Units	(6)	(6)	Ordinary Shares	9,552	(4)	D

Explanation of Responses:

1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.

2. The warrants are fully vested and currently exercisable.

3. The restricted stock units vest on March 1, 2027 and have no expiration date.

4. Each restricted stock unit represents a contingent right to receive one ADS.

5. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.

6. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

Remarks:

EVP & Head of Research & Product Development

	/s/ Michael Wolff Jensen as attorney-in-fact for Kennett Sprogoe	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Ascendis Pharma (ASND) Form 3 filing by SPROGOE KENNETT show?

The Form 3 shows SPROGOE KENNETT’s existing equity holdings in Ascendis Pharma, including warrants, restricted stock units, and Ordinary Shares. It is an initial ownership report, not a record of new share purchases or sales.

What warrant positions are reported in the Ascendis Pharma (ASND) Form 3?

The filing reports fully vested, currently exercisable warrants over 5,313, 45,000, 27,000, 22,755 and 14,504 Ordinary Shares at exercise prices from $37.18 to $176.28. Each position has specified expiration dates between 2027 and 2031.

How many restricted stock units does SPROGOE KENNETT hold in Ascendis Pharma (ASND)?

The officer holds three RSU awards covering 4,246, 3,197 and 9,552 underlying Ordinary Shares. These restricted stock units begin vesting on March 1, 2027 in one‑, two‑, and three‑year installment schedules and have no expiration date.

How many Ascendis Pharma (ASND) Ordinary Shares does SPROGOE KENNETT own directly and indirectly?

The Form 3 reports 19,460 Ordinary Shares held directly and 110 Ordinary Shares held indirectly through the officer’s children. These ordinary share positions are separate from any warrants or restricted stock units disclosed in the filing.

How are American Depositary Shares treated in the Ascendis Pharma (ASND) Form 3?

The footnotes state that each American Depositary Share represents one Ordinary Share of Ascendis Pharma. They also explain that each restricted stock unit represents a contingent right to receive one ADS, tying RSU awards directly to the underlying Ordinary Shares.